Cipla announced that the United States Food and Drug Administration (USFDA) has classified the routine current Good Manufacturing Practices (cGMP) inspection of its Kurkumbh manufacturing facility, as Voluntary Action Indicated (VAI).Powered by Capital Market - Live News

Cipla has allotted 35,106 fully paid-up equity shares of Rs 2 each, pursuant to exercise of employee stock options / stock appreciation rights under the Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company.Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs 1,61,51,06,210 comprising of 80,75,53,105 equity shares of face value Rs 2 each.Powered by Capital Market - Live News

Cipla will hold a meeting of the Board of Directors of the Company on 26 July 2024.Powered by Capital Market - Live News

Cipla announced that the United States Food and Drug Administration (USFDA) vide communication dated 25 June 2024 has classified the inspection of the company`s manufacturing facility in Patalganga as Voluntary Action Indicated (VAI). Powered by Capital Market - Live News

Cipla`s manufacturing unit in Goa has received six observations in Form 483 following USFDA inspection from 10 June to 21 June 2024. Powered by Capital Market - Live News